Preclinical trials indicated that dual-signaling CAR-T cells had stronger anti-tumor activity than single-expression of CAR-T cells (CD19-CAR-T cells or CD123-CAR-T cells) or the mixed combination of CAR-T cells (CD19-CAR-T cells and CD123-CAR-T cells), and could better prevent disease recurrence caused by downregulation or loss of target antigens on the tumor cell surface. This evidence concerns the gene CD19 and neoplasm.